Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1787Neoplasms 1504Carcinoma, Non-Small-Cell Lung 1046Prostatic Neoplasms 962Colorectal Neoplasms 881Lung Neoplasms 805Pancreatic Neoplasms 572Carcinoma, Hepatocellular 545Leukemia, Myeloid, Acute 542Stomach Neoplasms 514Ovarian Neoplasms 507Neoplasm Metastasis 501Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 369Brain Neoplasms 365Uterine Cervical Neoplasms 361Head and Neck Neoplasms 358Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 311Lymphoma 306Endometrial Neoplasms 304Triple Negative Breast Neoplasms 301Glioblastoma 300Rectal Neoplasms 284Sarcoma 267Urinary Bladder Neoplasms 266Hematologic Neoplasms 265Colonic Neoplasms 255

Interventions

sodium glycididazole 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Chemoradiotherapy × Clear all
NCT06667622 2024-10-31

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡